Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine augmentation of antipsychotics in chronic schizophrenia
IRCT20190530043769N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Rivastigmine augmentation with Placebo augmentation (2 arms). Primary endpoints: Quality of life, Positive symptoms of schizophrenia and 2 more. Started Feb 2021; status: completed.
02
Drugs
rivastigmine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20190530043769N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190530043769N1.